# LILA BIOLOGICS, INC.: Development of a Novel Integrin Antagonist for the Treatment of Pulmonary Hypertension

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | LILA BIOLOGICS, INC. |
| Location | SEATTLE, WA |
| Project | Development of a Novel Integrin Antagonist for the Treatment of Pulmonary Hypertension |
| Project number | 1R44HL184806-01 |
| Mechanism | R44 |
| Institute | National Heart Lung and Blood Institute |
| Award | $605,981 |
| Awarded | 2026-09-04 |
| Project period | 2026-09-05 to 2027-08-31 |
| UEI | TUBMVTWMQZC5 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11315115). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.